Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) solutions for Department of Homeland Security (DHS) applications, today reported that the company has received a previously unannounced order from the Canadian Air Transport Security Authority (CATSA) for up to 122 of its industry-leading QS-B220 desktop explosives trace detectors. These systems are planned to be deployed during the first half of 2016 (i.e., during Implant Sciences' current fiscal year ending June 30) to a number of Canadian airports for passenger and baggage screening.
"Implant Sciences' next generation non-rad trace detection technology has revolutionized the ETD industry," stated Dr. Darryl Jones, Implant Sciences' Executive Vice President. "The only fully-certified non-rad ETD on the market, the QS-B220 has been selected and deployed over the past year by numerous high-profile customers around the world, including the U.S. TSA, major European airports across 11 different countries, and now CATSA. We are pleased with this widespread adoption of our ETD technology and look forward to continuing this trend as we drive forward as the innovators of the ETD market."
"Implant Sciences is pleased that CATSA has selected the QS-B220 to meet the needs of their airports," stated Todd Swearingen, General Manager, Americas for Implant Sciences. "We are committed to elevating passenger experience while improving the security of aviation screening processes, and we are excited to deploy our technology to Canadian airports soon."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source: Implant Sciences Corporation
Date: Jan 19, 2016